Yujin Hoshida

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. pmc Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges
    Yujin Hoshida
    Mount Sinai Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Cancer Drug Targets 12:1129-59. 2012
  2. pmc Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis
    Yujin Hoshida
    Mount Sinai Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
    Gastroenterology 144:1024-30. 2013
  3. doi request reprint Gene signatures in the management of hepatocellular carcinoma
    Yujin Hoshida
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York 10029, USA
    Semin Oncol 39:473-85. 2012
  4. pmc Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
    Anja Lachenmayer
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, New York, NY 10029, USA
    J Hepatol 56:1343-50. 2012
  5. pmc Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib
    Anja Lachenmayer
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Cancer Res 18:4997-5007. 2012
  6. pmc MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a
    Sara Toffanin
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, New York, New York, USA
    Gastroenterology 140:1618-28.e16. 2011
  7. pmc Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
    Pippa Newell
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Hepatol 51:725-33. 2009
  8. pmc Gene-expression signature of vascular invasion in hepatocellular carcinoma
    Beatriz Minguez
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Surgical Oncology, Department of Surgery, Department of Pathology, Department of Preventive Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Hepatol 55:1325-31. 2011
  9. pmc Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma
    Kate Revill
    Cancer Genome Center, Cold Spring Harbor Laboratory, Woodbury, New York Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York Electronic address
    Gastroenterology 145:1424-35.e1-25. 2013
  10. doi request reprint UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma
    Raksha Mudbhary
    Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
    Cancer Cell 25:196-209. 2014

Collaborators

Detail Information

Publications14

  1. pmc Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges
    Yujin Hoshida
    Mount Sinai Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Cancer Drug Targets 12:1129-59. 2012
    ..In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice...
  2. pmc Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis
    Yujin Hoshida
    Mount Sinai Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
    Gastroenterology 144:1024-30. 2013
    ..We investigated whether a liver-derived 186-gene signature previously associated with outcomes of patients with HCC is prognostic for patients with newly diagnosed cirrhosis but without HCC...
  3. doi request reprint Gene signatures in the management of hepatocellular carcinoma
    Yujin Hoshida
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York 10029, USA
    Semin Oncol 39:473-85. 2012
    ..Recent updates of HCC gene signatures as well as emerging alternative modalities are also overviewed...
  4. pmc Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
    Anja Lachenmayer
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, New York, NY 10029, USA
    J Hepatol 56:1343-50. 2012
    ..We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor panobinostat alone and in combination with sorafenib in preclinical models of liver cancer...
  5. pmc Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib
    Anja Lachenmayer
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Cancer Res 18:4997-5007. 2012
    ..We aimed to characterize Wnt-pathway aberrations in HCC patients, and to investigate sorafenib as a potential Wnt modulator in experimental models of liver cancer...
  6. pmc MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a
    Sara Toffanin
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, New York, New York, USA
    Gastroenterology 140:1618-28.e16. 2011
    ..MicroRNAs (miRNAs) are involved in HCC pathogenesis, and their expression profiles have been used to classify cancers. We analyzed miRNA expression in human HCC samples to identify molecular subclasses and oncogenic miRNAs...
  7. pmc Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
    Pippa Newell
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Hepatol 51:725-33. 2009
    ..We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models...
  8. pmc Gene-expression signature of vascular invasion in hepatocellular carcinoma
    Beatriz Minguez
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Surgical Oncology, Department of Surgery, Department of Pathology, Department of Preventive Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Hepatol 55:1325-31. 2011
    ..While macroscopic vascular invasion can be detected by radiological techniques, pre-operative detection of microscopic vascular invasion, which complicates 30-40% of patients with early tumors, remains elusive...
  9. pmc Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma
    Kate Revill
    Cancer Genome Center, Cold Spring Harbor Laboratory, Woodbury, New York Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York Electronic address
    Gastroenterology 145:1424-35.e1-25. 2013
    ..To identify clinically relevant tumor suppressor genes silenced by DNA methylation in HCC, we integrated DNA methylation data from human primary HCC samples with data on up-regulation of gene expression after epigenetic unmasking...
  10. doi request reprint UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma
    Raksha Mudbhary
    Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
    Cancer Cell 25:196-209. 2014
    ..We propose that UHRF1 overexpression is a mechanism underlying DNA hypomethylation in cancer cells and that senescence is a primary means of restricting tumorigenesis due to epigenetic disruption. ..
  11. pmc Molecular sampling of prostate cancer: a dilemma for predicting disease progression
    Andrea Sboner
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA
    BMC Med Genomics 3:8. 2010
    ..Hence, we sought to develop a molecular panel for prostate cancer progression by reasoning that molecular profiles might further improve current clinical models...
  12. pmc Pivotal role of mTOR signaling in hepatocellular carcinoma
    Augusto Villanueva
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Gastroenterology 135:1972-83, 1983.e1-11. 2008
    ..We evaluated mTOR signaling in human HCC, as well as the antitumoral effect of a dual-level blockade of the mTOR pathway...
  13. doi request reprint Transcriptome Profiling of Archived Sectioned Formalin-Fixed Paraffin-Embedded (AS-FFPE) Tissue for Disease Classification
    Kensuke Kojima
    Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
    PLoS ONE 9:e86961. 2014
    ....
  14. pmc Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation
    Mirko Tarocchi
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Hepatology 54:522-31. 2011
    ..Whereas KLF6 overexpression in HCC cell lines and primary hepatocytes led to reduced MDM2 levels and increased p53 protein and transcriptional activity, reduction in KLF6 by small interfering RNA led to increased MDM2 and reduced p53...